Veradermics, Inc
MANE NYSE· Pharmaceutical Preparations
Last close · Oct 23, 2026
$138.78
KIRA · Stoqly’s AI analyst, in plain words
- Veradermics, Inc lost $70.0M in fiscal 2025.
- Free cash flow was −$71.6M in fiscal 2025, — of revenue.
Market cap
$5.6B
P/E
—
Revenue
—
Net income
−$70.0M
Free cash flow
−$71.6M
Operating margin
—
Veradermics, Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$70.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Veradermics, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Veradermics, Inc
- CIK
- 0001827635
Veradermics, Inc · MANE
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$26.5M | −$70.0M |
| Diluted EPS | −$37.05 | −$111.91 |
| Cash | ||
| Cash from operations | −$23.7M | −$71.6M |
| Capital expenditure | $0.0M | $0.0M |
| Free cash flow | −$23.7M | −$71.6M |
| Share count change | — | 1.1% |
| Debt and strength | ||
| Cash and short-term investments | $53.1M | $142M |
| Shareholders' equity | −$48.5M | −$121M |
| Current ratio | 11.8x | 16.7x |
| Interest coverage | −45.8x | — |
| Returns and quality | ||
| Altman Z'' | −10.9 | −13.5 |
Insiders bought, 12 months
$53.1M
5 insiders
Insiders sold, 12 months
$103M
4 insiders
Of sales under plans
12%
$12.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Veradermics, Inc · MANE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $138.78 a share, the company is worth $5.6B.
Source: SEC EDGAR XBRL filings (CIK 0001827635). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.